Related Experiment Video

Updated: Oct 25, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

76

Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements

Cindy Neuzillet1

  • 1Department of Medical Oncology, Curie Institute, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud 92210, France.

The Lancet. Gastroenterology & Hepatology
|August 6, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.6K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.1K

Related Experiment Videos

Last Updated: Oct 25, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

76
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.6K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K

Articles linked to this work by shared authors, journal, and citation graph.

[Sarcopenia in gastrointestinal oncology: Diagnostic criteria, clinical implications and management].

Bulletin du cancer·2026

[Metastatic or unresectable recurrent anal canal cancer: Therapeutic approaches and emerging perspectives].

Bulletin du cancer·2026

[Characteristics and performance of the new assessment method during the national digital interfaculty practice exams for the second cycle of medical education].

La Revue de medecine interne·2026

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

JHEP reports : innovation in hepatology·2026

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.

medRxiv : the preprint server for health sciences·2026

Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

The lancet. Gastroenterology & hepatology·2026

Strategies to develop therapeutic cancer vaccines for pancreatic cancer.

The lancet. Gastroenterology & hepatology·2026

Pain management in chronic pancreatitis: beyond opioids.

The lancet. Gastroenterology & hepatology·2026

Short-course prophylaxis with the Toronto HCV protocol for recipients of non-liver solid organ transplants from donors with hepatitis C viraemia: a retrospective, matched cohort study.

The lancet. Gastroenterology & hepatology·2026

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial.

The lancet. Gastroenterology & hepatology·2026

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study.

The lancet. Gastroenterology & hepatology·2026

Gut microbiome-related plasma metabolites and risk of colorectal cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Real-world screening for metabolic dysfunction-associated steatotic liver disease among adults with type 2 diabetes.

Proceedings (Baylor University. Medical Center)·2026

Identification of prediagnostic proteomic biomarkers for colon and rectal cancer in 3 prospective cohorts.

Journal of the National Cancer Institute·2026

Progress in the Mechanism of Heat Shock Proteins in Gastric Cancer: From Biomarkers to Therapeutic Targets.

Immunity, inflammation and disease·2026

H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer.

Cancer discovery·2026

Advances in Biomarkers and Novel Therapeutics in Renal Cell Carcinoma: Evidence from Recent Clinical Trials.

Reviews on recent clinical trials·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us